Table 2.
Summary of death, dropout, and cardiovascular-related hospitalization visits
| Event | Placebo (n = 177) | Tafamidis 20 mg (n = 88) | Tafamidis 80 mg (n = 176) | Pooled tafamidis (n = 264) | All patients (n = 441) |
|---|---|---|---|---|---|
| All-cause mortality | 76 (42.9) | 24 (27.3) | 54 (30.7) | 78 (29.5) | 154 (34.9) |
| Dropouta | 50 (28.3) | 14 (15.9) | 32 (18.2) | 46 (17.4) | 96 (21.8) |
| CV-related hospitalizations | |||||
| 0 | 70 (39.5) | 46 (52.3) | 80 (45.5) | 126 (47.7) | 196 (44.4) |
| 1 | 53 (29.9) | 22 (25.0) | 46 (26.1) | 68 (25.8) | 121 (27.4) |
| 2 | 23 (13.0) | 10 (11.4) | 28 (15.9) | 38 (14.4) | 61 (13.8) |
| 3 | 16 (9.0) | 5 (5.7) | 15 (8.5) | 20 (7.6) | 36 (8.2) |
| 4 | 4 (2.3) | 2 (2.3) | 4 (2.3) | 6 (2.3) | 10 (2.3) |
| 5 | 3 (1.7) | 2 (2.3) | 1 (0.6) | 3 (1.1) | 6 (1.4) |
| 6 | 4 (2.3) | 0 | 1 (0.6) | 1 (0.4) | 5 (1.1) |
| 7 | 3 (1.7) | 0 | 1 (0.6) | 1 (0.4) | 4 (0.9) |
| 8 | 1 (0.6) | 1 (1.1) | 0 | 1 (0.4) | 2 (0.5) |
Data are presented as n (%)
CV cardiovascular
aDropout is only related to the recording of hospitalizations; there were no dropouts in the recording or follow-up on death